AXQ Capital’s AbbVie ABBV Stock Holding History

AXQ Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,469	Closed	-$564K	–	975
2025 Q4	$564K	Buy	2,469 +1,336	+118%	+$304K	0.13%	266
2025 Q3	$262K	Sell	1,133 -8,845	-89%	-$1.8M	0.1%	360
2025 Q2	$1.85M	Buy	9,978 +1,762	+21%	+$327K	0.6%	16
2025 Q1	$1.72M	Buy	+8,216	New	+$1.6M	0.69%	13
2024 Q4	–	Sell	-9,425	Closed	-$1.86M	–	413
2024 Q3	$1.86M	Buy	+9,425	New	+$1.76M	0.56%	23
2024 Q2	–	Sell	-3,700	Closed	-$674K	–	425
2024 Q1	$674K	Buy	+3,700	New	+$638K	0.16%	224
2023 Q3	–	Sell	-2,900	Closed	-$391K	–	453
2023 Q2	$391K	Buy	+2,900	New	+$425K	0.48%	68
2023 Q1	–	Sell	-6,881	Closed	-$1.11M	–	469
2022 Q4	$1.11M	Buy	+6,881	New	+$1.06M	0.77%	22

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AXQ Capital's ABBV Position: Q1 2026 in Review

AXQ Capital sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 2,469 shares — an estimated $564K sold.

AXQ Capital first reported a position in ABBV in Q4 2022 and held it in 8 quarters. The position peaked at $1.86M in Q3 2024. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

AXQ Capital reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
AXQ Capital sold 2,469 AbbVie shares in Q1 2026, an estimated $564K.
AXQ Capital first reported a position in AbbVie in Q4 2022 and held it in 8 quarters.
AXQ Capital's AbbVie position peaked at $1.86M in Q3 2024.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on AXQ Capital's 13F filing for Q1 2026, filed 13 May 2026.